Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1205)	2/26/2004 5:51:55 PM
From: quidditch	Read Replies (1) \| Respond to of 1834

Interesting. Can DOVP's interest be far behind? If Wyeth B/D approves (interesting in and of itself that this rises to that level and that B/D approval hadn't been obtained before the announcement), then NBIX is licensor and sub-licensee, subject only to DOVP's interest. Certainly seems as though it would smooth the way for a further PFE transaction with NBIX. All on the eve of an ESTORRA decision. Is this equivalent to JJackson's garment malfunction stealing SBowl thunder? quid

To: Icebrg who wrote (1205)	2/26/2004 9:04:17 PM
From: Biomaven	Read Replies (1) \| Respond to of 1834

Anyone have any idea what the milestones that WYE is giving up amounted to? If we knew that number we could then value the 2 1/2% royalty stream. (Which of course is interesting both in its own right and because of the remaining DOVP royalty valuation). Peter